All Updates

All Updates

icon
Filter
Partnerships
Enveric Biosciences signs licensing agreement with MindBio Therapeutics to develop NPP candidate
Psychedelic Medicine
May 14, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Yesterday
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Yesterday
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Yesterday
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Yesterday
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Yesterday
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Yesterday
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Yesterday
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Yesterday
Psychedelic Medicine

Psychedelic Medicine

May 14, 2024

Enveric Biosciences signs licensing agreement with MindBio Therapeutics to develop NPP candidate

Partnerships

  • Florida-based biotechnology company Enveric Biosciences has signed a non-binding agreement to out-license its class of novel psilocin prodrugs (NPP) to Vancouver-based biotechnology company MindBio Therapeutics.

  • Under the terms of the partnership, MindBio will leverage Enveric's NPP molecules, which are designed to release therapeutic levels of systemic psilocin, to advance the treatment of neuropsychiatric conditions like depression. Further, MindBio would undertake all future preclinical, clinical, and commercial development, paying Enveric development and sales milestones a total of USD 66.5 million upon meeting certain conditions, along with future sales royalties. Additionally, MindBio would have the right to sublicense the technology and cash buyout options as part of the agreement.

  • MindBio Therapeutics is a leading biotech company focused on developing novel treatments for mental health conditions. It specializes in microdosing psychedelic medicines and is conducting clinical trials targeting major depressive disorder and existential distress in cancer patients.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.